Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) CFO Alan A. Musso sold 17,117 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the transaction, the chief financial officer now directly owns 31,585 shares in the company, valued at $294,688.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) traded up $0.36 during trading hours on Wednesday, reaching $8.87. 422,527 shares of the company were exchanged, compared to its average volume of 592,063. Bellicum Pharmaceuticals, Inc. has a 1-year low of $7.41 and a 1-year high of $16.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 77.16%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.03 million. During the same period last year, the firm earned ($0.66) earnings per share. Bellicum Pharmaceuticals’s revenue for the quarter was up 18.2% compared to the same quarter last year. equities research analysts anticipate that Bellicum Pharmaceuticals, Inc. will post -2.93 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in BLCM. Point72 Asset Management L.P. bought a new position in Bellicum Pharmaceuticals in the 3rd quarter valued at about $4,723,000. JPMorgan Chase & Co. increased its holdings in Bellicum Pharmaceuticals by 10.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock valued at $28,811,000 after buying an additional 227,668 shares during the period. Vanguard Group Inc. increased its holdings in Bellicum Pharmaceuticals by 17.8% in the 1st quarter. Vanguard Group Inc. now owns 1,061,582 shares of the biopharmaceutical company’s stock valued at $13,100,000 after buying an additional 160,151 shares during the period. Numeric Investors LLC bought a new position in Bellicum Pharmaceuticals in the 2nd quarter valued at about $1,137,000. Finally, Goldman Sachs Group Inc. increased its holdings in Bellicum Pharmaceuticals by 223.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock valued at $1,612,000 after buying an additional 95,336 shares during the period. 55.50% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently commented on BLCM. Raymond James Financial reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, September 18th. Jefferies Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. Finally, BidaskClub raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $26.20.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/13/bellicum-pharmaceuticals-inc-blcm-cfo-sells-159701-61-in-stock.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.